Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Sponsors
Cipla Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Female patient of more than or equal to 18 years of age Previously treated or newly diagnosed ovarian primary peritoneal or fallopian tube cancer patients prescribed on Olaparib na ve or initiated equal to or less than 3 months Mutation status BRCA positive or HRD plus BRCA negative or HRD positive
Exclusion criteria
Exclusion criteria: Failed to provide written informed consent Any medical condition that in the opinion of the investigator would interfere with safe completion of the study, or were participating in any other clinical
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Baseline demography including molecular characteristics age gender comorbidities primary treatment family history BRCA1 BRCA2 mutation and HRD statusTimepoint: Baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Assess the co-relation of BRCA and HRD status Lifestyle medical history and symptoms Family history Histopathologic type of OC Previous lines of treatmentTimepoint: Baseline | — |
Countries
India
Contacts
Public ContactDr Devang Sarvaiya
Cipla Limited
Outcome results
None listed